CAMBRIDGE, Mass., May 10 /PRNewswire/ -- Peptimmune, Inc., a privately
held biopharmaceutical company announced the appointments of Jose-Carlos
Gutierrez-Ramos, Ph.D. as Vice President, Research and Development and Chief
Scientific Officer; and Christine Blumhardt, Pharm.D. as Vice President,
Regulatory Affairs and Quality Assurance. Reporting to Thomas P. Mathers,
President and CEO, both of them will play critical roles in the advancement of
Peptimmune's programs through clinical development and in shaping the overall
business strategy of the company.
"I am delighted to have two people with such extraordinary experience and
strategic insight, join Peptimmune's management team," stated Mr. Mathers.
"Their impressive combination of scientific expertise and business acumen will
be an invaluable asset to our company. Jose-Carlos' success in advancing
immunology candidates through the clinic, make him and ideal leader of
Peptimmune's research and development programs, and Christine's more than 20
years of experience will provide us with the regulatory expertise to move our
preclinical programs into clinical development."
Dr. Gutierrez is a highly regarded scientist with significant expertise in
Immunology and product development. He most recently served as CSO of a
Spanish biotechnology company, Genetrix, where he led the spin out of several
technologies from the Spanish Research Council. Prior to Genetrix, Dr.
Gutierrez served as Vice President, Inflammation at Millennium
Pharmaceuticals, where he led a group of more than 100 scientists.
Importantly, in that role he was responsible for advancing preclinical
candidates in Immunology to human trials and advancing compounds through
clinical development. Dr. Gutierrez was also Assistant Professor for Medicine
at the Harvard Medical School, where he led a major research team at the
Center for Blood Research.
Dr. Blumhardt has more than 20 years of experience in regulated clinical
research and in the pharmaceutical industry. She completed 5 years of post-
doctoral fellowship training in clinical research at the National Institutes
of Health, served as an Interagency Agreement Officer in FDA's Division of
Neuropharmacologic Drugs, and held leadership positions for 13 years in
Clinical and Regulatory Affairs at GlaxoSmithKline. Most recently she served
as Vice President Global Product Development, Worldwide Regulatory Affairs at
Wyeth Pharmaceuticals, where she was responsible for the company's global
regulatory development strategy and operations for all compounds (including
pharmaceuticals, biologicals vaccines and devices) across all therapeutic
areas.
About Peptimmune, Inc.
Peptimmune, Inc. is a privately held clinical stage biotechnology company
focused on utilizing both novel and proven technologies to improve the
therapeutic management of chronic autoimmune and metabolic disorders. The
company is developing second generation therapeutics that are expected to
result in safer and more effective products for obesity, multiple sclerosis,
rheumatoid arthritis and pemphigus vulgaris. Founded by a team of world class
scientists and led by an experienced management team, Peptimmune's mission is
to reduce the burden these diseases place on the individuals, their families
and the healthcare system. For additional information, visit the company's
website at http://www.peptimmune.com.
SOURCE Peptimmune, Inc.
 back to top
Related links:
http://www.peptimmune.com
CONTACT:
Thomas P. Mathers, President and Chief
Executive Officer of Peptimmune, +1-617-715-8040,
tom.mathers@peptimmune.com
|
